How Much Does Crestor (Rosuvastatin) Cost in Connecticut in 2026?

Brand vs. Generic Pricing in Connecticut

The single biggest factor in what you pay for rosuvastatin in Connecticut is whether you fill brand-name Crestor or a generic equivalent. Brand Crestor carries a manufacturer list price near $290 per month from AstraZeneca. Generic rosuvastatin, by contrast, averages roughly $15 per month across Connecticut retail pharmacies in 2026.

That price gap is not unusual for statins that have lost patent exclusivity. Crestor's U.S. patent expired in 2016, and several generic manufacturers now produce rosuvastatin calcium tablets in 5 mg, 10 mg, 20 mg, and 40 mg strengths. The FDA's Orange Book lists multiple approved ANDA holders for rosuvastatin, which drives retail competition and keeps generic prices low.

Prices vary by pharmacy. A cash-pay customer filling a 30-day supply of generic rosuvastatin 10 mg at a large chain pharmacy in Hartford or Stamford may pay $8 to $20 depending on the chain's pricing tier. Independent pharmacies sometimes charge slightly more. Costco and warehouse clubs tend to sit at the low end even without a membership-linked discount. If you are paying cash (no insurance), always ask the pharmacy for their lowest available generic price before filling the prescription.

The JUPITER trial (N=17,802) established rosuvastatin 20 mg as the first statin to demonstrate primary prevention benefit in patients with elevated high-sensitivity C-reactive protein (hsCRP) but LDL-C below 130 mg/dL. Over a median 1.9 years of follow-up, the rosuvastatin group experienced a 44% relative reduction in the primary cardiovascular endpoint compared with placebo 1. That trial cemented rosuvastatin's place in guidelines and expanded its prescribing base well beyond secondary prevention.

Connecticut Medicaid Coverage for Rosuvastatin

Connecticut Medicaid, administered through HUSKY Health (the state's Medicaid managed care program), covers rosuvastatin with prior authorization. This means your prescriber must submit clinical documentation before the pharmacy can fill the prescription under Medicaid. The PA requirement typically exists because the state's preferred drug list (PDL) may favor other statins (such as atorvastatin or simvastatin) as first-line options.

Getting PA approval usually takes one to three business days. Your prescriber's office submits the request to the managed care organization. Common approval criteria include documented intolerance to a preferred statin, failure to reach LDL-C goals on a preferred agent, or a clinical indication where rosuvastatin is specifically supported by guidelines.

The 2018 AHA/ACC Cholesterol Clinical Practice Guideline identifies rosuvastatin 20 to 40 mg as one of only two high-intensity statin options (alongside atorvastatin 40 to 80 mg) for patients requiring at least a 50% LDL-C reduction 2. If your prescriber documents that you need high-intensity therapy and have a reason to avoid atorvastatin, PA approval is typically straightforward.

For Connecticut residents enrolled in Medicare Part D rather than Medicaid, rosuvastatin coverage depends on the specific plan formulary. Most Part D plans cover generic rosuvastatin at Tier 1 or Tier 2 copay levels, meaning out-of-pocket costs often fall between $0 and $15 per month after the deductible.

Compounded Rosuvastatin in Connecticut

Compounded rosuvastatin is available in Connecticut through licensed 503A pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. Connecticut's Department of Consumer Protection regulates these pharmacies, and the state permits compounding of commercially available drugs when a prescriber documents a patient-specific clinical need (such as an allergy to a filler in the manufactured tablet, difficulty swallowing, or a non-standard dose requirement).

Compounded formulations can include oral suspensions for patients who cannot swallow tablets, or capsules with alternative inactive ingredients for patients with dye sensitivities. Pricing for compounded rosuvastatin varies by pharmacy but can be comparable to or lower than brand pricing, particularly for patients whose insurance does not cover the compounded version.

One consideration: compounded drugs are not FDA-approved finished products. The FDA has noted that compounded medications do not undergo the same premarket review for safety, efficacy, and quality as approved drugs 3. Patients using compounded rosuvastatin should confirm their pharmacy holds a valid Connecticut compounding license and follows current USP standards.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans available on Connecticut's Access Health CT marketplace cover generic rosuvastatin. The state's major carriers (Anthem Blue Cross Blue Shield, ConnectiCare, Aetna) all include generic rosuvastatin on their formularies, generally at preferred generic copay tiers. Monthly copays through commercial insurance typically range from $0 to $15 for generic rosuvastatin.

Brand-name Crestor is a different story. Many plans either exclude brand Crestor entirely or place it on a non-preferred brand tier with copays of $50 to $100 or more. Some plans require step therapy, meaning you must try and fail on generic rosuvastatin before they will cover brand Crestor. Given that the active ingredient is identical, few patients have a clinical reason to insist on brand-name Crestor over the generic.

For patients with employer-sponsored insurance, coverage terms vary by plan. Check your formulary or call the number on your insurance card to confirm tier placement and any applicable prior authorization requirements. The rosuvastatin FDA label lists approved dosing from 5 mg to 40 mg once daily, and all strengths are typically covered at the same copay tier within a given plan.

A 2023 analysis published in JAMA found that statin use among eligible U.S. adults remains below guideline-recommended levels, with cost and access barriers cited as contributing factors 4. Removing cost friction through generic substitution and insurance coverage directly supports adherence.

Discount Programs and Savings Cards

Several pathways exist for reducing out-of-pocket costs on rosuvastatin in Connecticut beyond insurance.

Manufacturer savings cards. AstraZeneca has historically offered copay savings cards for brand Crestor. These cards typically reduce the patient's copay to $3 to $30 per month for commercially insured patients. They do not apply to government insurance (Medicaid, Medicare, Tricare). Eligibility and terms change periodically, so verify current offers directly through the manufacturer's website or your pharmacy.

Pharmacy discount programs. Several large chains operating in Connecticut offer generic drug discount lists. Walmart, for example, includes select generic statins on its $4/$10 program (30-day and 90-day supplies, respectively). CVS Health, Walgreens, and Rite Aid each have their own discount card programs. These programs are available to uninsured or underinsured patients and sometimes beat insurance copays.

GoodRx and similar aggregators. Coupon platforms aggregate negotiated prices across pharmacies. A GoodRx search for rosuvastatin 10 mg in Connecticut typically shows cash prices between $8 and $18 for a 30-day supply, depending on location. These coupons are free to use but cannot be combined with insurance.

Patient assistance programs. For uninsured patients who do not qualify for Medicaid, AstraZeneca's AZ&Me program may provide brand Crestor at no cost. Income eligibility thresholds apply (generally at or below 400% of the federal poverty level). Application requires prescriber involvement and proof of income.

The 2019 ACC/AHA Primary Prevention Guideline specifically recommends clinician-patient discussion of cost when selecting statin therapy, noting that adherence improves when patients can afford their medication 5. Generic rosuvastatin at $15 per month or less makes this conversation simpler than it was a decade ago.

Telehealth Prescribing in Connecticut

Connecticut permits telehealth prescribing of rosuvastatin. The state's telehealth parity law (Connecticut General Statutes § 19a-906) requires insurers to cover telehealth services on the same terms as in-person visits. A prescriber can evaluate your lipid panel, assess cardiovascular risk, and write a rosuvastatin prescription during a video or audio visit.

This is relevant for Connecticut residents in rural areas of Litchfield or Windham counties who may live 30 or more minutes from the nearest lipid clinic. Telehealth removes the geographic barrier. It also reduces visit costs: many telehealth platforms charge $20 to $75 per visit without insurance, compared to $150 or more for an in-person office visit.

For ongoing statin management, the 2018 AHA/ACC guideline recommends fasting lipid panel assessment 4 to 12 weeks after initiating therapy, then every 3 to 12 months thereafter 2. Patients can get labs drawn at any Quest Diagnostics or LabCorp location in Connecticut (both have multiple sites across the state), then review results via telehealth with their prescriber.

One practical note: Connecticut law requires that the prescriber be licensed in Connecticut or hold a valid telemedicine license to practice in the state. Out-of-state telehealth platforms must verify their prescribers meet this requirement.

How Rosuvastatin Compares on Efficacy and Cost

Rosuvastatin is the most potent statin on a milligram-for-milligram basis. At 10 mg, rosuvastatin lowers LDL-C by approximately 46%, compared to roughly 37% for atorvastatin 10 mg 6. This means some patients can achieve target LDL-C levels at a lower rosuvastatin dose than they would need with atorvastatin.

From a cost perspective in Connecticut, both generic rosuvastatin and generic atorvastatin sit in the same low price range ($8 to $20 per month cash pay). The clinical choice between them often comes down to side-effect profile, drug interactions, and individual patient response rather than price. Rosuvastatin has fewer CYP3A4-mediated drug interactions than atorvastatin, which can matter for patients on medications like clarithromycin, itraconazole, or certain HIV protease inhibitors.

The STELLAR trial directly compared rosuvastatin across doses against atorvastatin, simvastatin, and pravastatin. Rosuvastatin 10 mg to 40 mg produced significantly greater LDL-C reductions than equivalent doses of the comparators across all dose levels studied 6. For Connecticut patients and prescribers weighing statin options, this potency advantage is clinically meaningful when aggressive LDL-C lowering is the goal.

Dosing, Safety, and Monitoring Basics

Rosuvastatin is taken once daily, with or without food. Starting doses for most adults range from 5 mg to 20 mg, depending on baseline LDL-C level, cardiovascular risk, and treatment goals. The maximum approved dose is 40 mg daily, reserved for patients who do not reach their LDL-C target on lower doses.

Patients of Asian descent may have higher systemic exposure to rosuvastatin. The FDA label recommends a starting dose of 5 mg in this population 7. Dose adjustment is also recommended for patients with severe renal impairment (creatinine clearance <30 mL/min), in whom the 5 mg starting dose should not be exceeded without careful monitoring.

Common side effects include myalgia (reported in 2% to 11% of patients across clinical trials), headache, nausea, and abdominal pain. Serious but rare risks include rhabdomyolysis and hepatotoxicity. Baseline liver function tests (ALT, AST) should be checked before starting therapy, with repeat testing if symptoms of liver injury develop.

A Cochrane systematic review of statins for primary prevention (N=94,283 across 18 trials) confirmed that statin therapy reduces all-cause mortality (RR 0.86 to 95% CI 0.79 to 0.94) and major cardiovascular events in individuals without established cardiovascular disease 8. The benefit-risk profile supports long-term use in appropriately selected patients.

Connecticut prescribers should document statin intensity category (moderate or high) and the patient's 10-year ASCVD risk score in the medical record, consistent with AHA/ACC recommendations. For patients on rosuvastatin 20 mg or 40 mg (high-intensity), the expected LDL-C reduction is 50% or greater from baseline.